Ratings Medivir AB Deutsche Boerse AG

Equities

MVR0

SE0020181014

Delayed Deutsche Boerse AG Other stock markets 15:50:03 2024-07-16 EDT			5-day change	1st Jan Change
0.228 ^EUR	+3.17%		-1.30%	+4.20%

06-27	Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma	CI
06-20	Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024.	CI

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEDIVIR AB	+4.20%	30.31M	-
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B	B+
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B	B+
ARGENX SE	+25.12%	27.87B	B
BIONTECH SE	-17.74%	20.95B	B+
GENMAB A/S	-15.36%	16.92B	A-
BEIGENE, LTD.	-15.21%	16.18B	B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B	C+
WUXI APPTEC CO., LTD.	-47.10%	14.79B	A-
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes